VBI Vaccines Inc. (NASDAQ:VBIV) price on Friday, March 17, fall -9.02% below its previous day’s close as a downside momentum from buyers pushed the stock’s value to $0.31.
A look at the stock’s price movement, the close in the last trading session was $0.34, moving within a range at $0.3027 and $0.3498. The beta value (5-Year monthly) was 1.91. Turning to its 52-week performance, $1.86 and $0.33 were the 52-week high and 52-week low respectively. Overall, VBIV moved -43.84% over the past month.
From Robots to Self-Driving Cars: 5 AI Stocks to Consider for Your Portfolio
The artificial intelligence (AI) revolution is already here and it's about to change everything we know about everything. With the global market for AI projected to grow from $137 billion in 2022 to over $1.81 trillion by 2030, there's never been a better time to invest in this burgeoning industry. That's why we've compiled a list of the Top 5 AI Stocks to Buy for 2023. These companies are at the forefront of the AI revolution, and have the potential to deliver huge returns to investors like you.
Get our free report, "Top 5 AI Stocks to Buy for 2023".
Sponsored
VBI Vaccines Inc.’s market cap currently stands at around $82.40 million, with investors looking forward to this quarter’s earnings report slated for May 08, 2023 – May 12, 2023. Analysts project the company’s earnings per share (EPS) to be -$0.08, which has seen fiscal year 2023 EPS growth forecast to increase to -$0.28 and about -$0.2 for fiscal year 2024. Per the data, EPS growth is expected to be 36.40% for 2023 and 28.60% for the next financial year.
Analysts have a consensus estimate of $820k for the company’s revenue for the quarter, with a low and high estimate of $630k and $1 million respectively. The average forecast suggests up to a 550.80% growth in sales growth compared to quarterly growth in the same period last fiscal year. Wall Street analysts have also projected the company’s year-on-year revenue for 2023 to grow to $6.62 million, representing a 511.80% jump on that reported in the last financial year.
Revisions could be used as tool to get short term price movement insight, and for the company that in the past seven days was no upward and no downward review(s). Turning to the stock’s technical picture we see that short term indicators suggest on average that VBIV is a 100% Sell. On the other hand, the stock is on average a 100% Sell as suggested by medium term indicators while long term indicators are putting the stock in 100% Sell category.
2 analyst(s) have given their forecast ratings for the stock on a scale of 1.00-5.00 for a strong buy to strong sell recommendation. A total of 0 analyst(s) rate the stock as a Hold, 1 recommend VBIV as a Buy and 1 give it an Overweight rating. Meanwhile, 0 analyst(s) rate the stock as Underweight and 0 say it is a Sell. As such, the average rating for the stock is Overweight which could provide an opportunity for investors keen on increasing their holdings of the company’s stock.
VBIV’s current price about -29.50% and -39.86% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 23.93, while 7-day volatility ratio is 11.23% and 10.19% in the 30-day chart. Further, VBI Vaccines Inc. (VBIV) has a beta value of 1.94, and an average true range (ATR) of 0.04. Analysts have given the company’s stock an average 52-week price target of $4.00, forecast between a low of $2.00 and high of $6.00. Looking at the price targets, the low is -545.16% off current price level while to achieve the yearly target high, price needs to move -1835.48%. Nonetheless, investors will most likely welcome a -1190.32% jump to $4.00 which is the analysts’ median price.
In the market, a comparison of VBI Vaccines Inc. (VBIV) and its peers suggest the former has performed considerably weaker. Data shows VBIV’s intraday price has changed -9.02% in last session and -79.82% over the past year. Comparatively, Pieris Pharmaceuticals Inc. (PIRS) has moved -12.95% on the day and only -60.20% in the past 12 months. Elsewhere, the overall performance for the S&P 500 and Dow Jones Industrial shows that the indexes are down -1.10% and -1.19% respectively in the last trading.
If we refocus on VBI Vaccines Inc. (NASDAQ:VBIV), historical trading data shows that trading volumes averaged 0.94 million over the past 10 days and 924.22K over the past 3 months. The company’s latest data on shares outstanding shows there are 258.26 million shares.
The 0.52% of VBI Vaccines Inc.’s shares are in the hands of company insiders while institutional holders own 44.40% of the company’s shares. Also important is the data on short interest which shows that short shares stood at 13.84 million on Feb 27, 2023, giving us a short ratio of 18.07. The data shows that as of Feb 27, 2023 short interest in VBI Vaccines Inc. (VBIV) stood at 5.36% of shares outstanding, with shares short rising to 12.91 million registered in Jan 30, 2023. Current price change has pushed the stock -21.58% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the VBIV stock continues to rise going into the next quarter.
